

Supplementary Material

TITLE: Frequency and impact on clinical outcomes of sarcopenia in patients with idiopathic pulmonary fibrosis

Authors:

Kohei Fujita M.D.,¹ Hirotsugu Ohkubo M.D., Ph.D.,¹ Akiko Nakano M.D., Ph.D.,² Yuta Mori M.D., Ph.D.,¹ Kensuke Fukumitsu M.D., Ph.D.,¹ Satoshi Fukuda M.D., Ph.D.,¹ Yoshihiro Kanemitsu M.D., Ph.D.,¹ Takehiro Uemura M.D., Ph.D.,¹ Tomoko Tajiri M.D., Ph.D.,¹ Ken Maeno M.D., Ph.D.,¹ Yutaka Ito M.D., Ph.D.,¹ Tetsuya Oguri M.D., Ph.D.,¹ Yoshiyuki Ozawa M.D., Ph.D.,³ Takayuki Murase M.D., Ph.D.,⁴ and Akio Niimi M.D., Ph.D.¹

Institutional affiliation:

¹Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

²Department of Respiratory Medicine, Nagoya City University East Medical Center, Nagoya, Japan.

³Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

⁴Department of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.

Corresponding author:


Hirotsugu Ohkubo, Department of Respiratory Medicine Allergy and Clinical

Immunology, Nagoya City University Graduate School of Medical Sciences, 1


Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan, **Fax:**

+81-52-852-0849, **Phone:** +81-52-853-8216, **E-mail:** hohkubo@med.nagoya-cu.ac.jp

Supplementary Figure S1. Frequency of non-severe and severe sarcopenia.



Supplementary Figure S2. The relationship of low muscle mass, low handgrip strength, and low gait speed in study populations.



Supplementary Table S1. Patients' characteristics with and without corticosteroid

use.

| Variable | With corticosteroids (n = 10) | Without corticosteroids (n = 44) | P-value |
|------------------------------------|--|---|----------------|
| Age, years | 77.1 ± 6.2 | 72.2 ± 7.7 | 0.067 |
| Gender, men, n (%) | 10 (100.0%) | 37 (84.1) | 0.231 |
| Body mass index, kg/m ² | 21.6 ± 3.7 | 22.4 ± 3.0 | 0.460 |
| Smoking status | | | |
| Current or ex-smoker, n (%) | 8 (80.0%) | 36 (81.8%) | 0.576 |
| Smoking history, pack-years | 30 [25–38] | 36 [8–46] | 0.923 |
| Pulmonary function test | | | |
| FVC, % predicted | 81.4 ± 16.7 | 79.9 ± 16.3 | 0.783 |
| FEV ₁ , % predicted | 85.0 ± 13.0 | 80.6 ± 15.5 | 0.408 |
| FEV ₁ /FVC, % | 83.0 ± 6.9 | 81.3 ± 9.1 | 0.589 |
| DL _{CO} , % predicted | 64.0 ± 22.8 | 66.9 ± 17.6 | 0.661 |
| GAP score | 4 [3–4] | 3 [3–4] | 0.173 |
| 6MWT | | | |
| 6MWD, m | 368 ± 101 | 411 ± 94 | 0.201 |
| Lowest SpO ₂ , % | 85 [83–91] | 89 [85–92] | 0.298 |
| SARC-F score | 3 [1–5] | 2 [1–3] | 0.100 |
| Sarcopenia, n (%) | 5 (50.0%) | 17 (38.6%) | 0.337 |

Data are presented as means (± standard deviation), medians [interquartile range], or numbers (%).

Abbreviations: BMI, body mass index; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1.0 second; DL_{CO}, diffusing capacity of the lung for carbon monoxide; GAP, gender, age and physiology; 6MWT, 6-minute walk test; 6MWD, 6-minute walk distance; SpO₂, oxygen saturation by pulse oximetry; SARC-F, strength,

assistance in walking, rising from a chair, climbing stairs, and falls.